Silica Corpora is a cutting-edge AI-based platform company founded in 2022 and headquartered in Berlin, Germany. The company specializes in designing and optimizing therapeutic antibodies targeting priority diseases. Using proprietary AI machine learning and data analytics working exclusively with amino acid sequences, Silica Corpora develops advanced De Novo solutions for antibody discovery.

The mission of Silica Corpora is to develop advanced De Novo solutions that result in enhanced quality and more cost-effective antibody therapeutics for diseases with high unmet need. The platform aims to revolutionize drug discovery by increasing efficiency, precision, and control in antibody candidate design.

The company's AI platform generates new antibody candidates from scratch, optimizes binding affinity, and predicts antibody properties such as developability, stability, solubility, self-aggregation, and immunogenicity. Modules include Generator, Discriminator, Optimizer, and Ep-Mapper, working holistically to produce candidates that meet program-specific target product profiles.

Founded by Tim Ermak (CTO) and Jaime Rosselló (CEO), with Anna-Catharina Krebs as Chief Scientific Officer, the team combines deep expertise in AI, drug discovery, and biochemistry. Additional advisors and experts contribute to branding, marketing, and business development.

Silica Corpora promotes values such as reducing animal testing, sustainability, democratizing drug discovery globally, and removing cost barriers to therapy development.

Silica Corpora GmbH, Am Friedrichshain 26, 10407 Berlin, Germany